GB1585615A - Composition and method for combating virus infections - Google Patents
Composition and method for combating virus infections Download PDFInfo
- Publication number
- GB1585615A GB1585615A GB27464/77A GB2746477A GB1585615A GB 1585615 A GB1585615 A GB 1585615A GB 27464/77 A GB27464/77 A GB 27464/77A GB 2746477 A GB2746477 A GB 2746477A GB 1585615 A GB1585615 A GB 1585615A
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- phosphonoformic acid
- viruses
- infections caused
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 37
- 239000000203 mixture Substances 0.000 title claims description 20
- 230000009385 viral infection Effects 0.000 title claims description 10
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 194
- 229960005102 foscarnet Drugs 0.000 claims description 97
- 150000003839 salts Chemical class 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 19
- 206010022000 influenza Diseases 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 241001529453 unidentified herpesvirus Species 0.000 claims description 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- -1 elixir Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 2
- 206010062639 Herpes dermatitis Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000004946 genital herpes Diseases 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 34
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 12
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 5
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000191938 Micrococcus luteus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
- TVMXBDVCDVAXLP-UHFFFAOYSA-L [Na+].[Na+].[Na+].[O-]S(=O)S([O-])(=O)=O Chemical compound [Na+].[Na+].[Na+].[O-]S(=O)S([O-])(=O)=O TVMXBDVCDVAXLP-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 238000002962 plaque-reduction assay Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- SRWFBFUYENBCGF-UHFFFAOYSA-M sodium;chloride;hydrochloride Chemical compound [Na+].Cl.[Cl-] SRWFBFUYENBCGF-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 229950010342 uridine triphosphate Drugs 0.000 description 2
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- SWMBOMMGMHMOHE-MHLULTLJSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SWMBOMMGMHMOHE-MHLULTLJSA-N 0.000 description 1
- KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 1
- UWJDLABDOBGBFS-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].[Na].OC(=O)CC(O)(C(O)=O)CC(O)=O UWJDLABDOBGBFS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001036151 Aichi virus 1 Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- BDWCBOUQHJMMPD-UHFFFAOYSA-K [O-]C(P([O-])(O)=O)=O.[O-]C(P(O)(O)=O)=O.[Na+].[Na+].[Na+] Chemical compound [O-]C(P([O-])(O)=O)=O.[O-]C(P(O)(O)=O)=O.[Na+].[Na+].[Na+] BDWCBOUQHJMMPD-UHFFFAOYSA-K 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- DJPPHVMKADFUKB-UHFFFAOYSA-N chloroform;dichloromethane;ethyl acetate Chemical compound ClCCl.ClC(Cl)Cl.CCOC(C)=O DJPPHVMKADFUKB-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- NQCBIMOYRRMVNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrochloride Chemical compound Cl.OCC(O)CO NQCBIMOYRRMVNA-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical class [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3886—Acids containing the structure -C(=X)-P(=X)(XH)2 or NC-P(=X)(XH)2, (X = O, S, Se)
- C07F9/3891—Acids containing the structure -C(=X)-P(=X)(XH)2, (X = O, S, Se)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7607496A SE7607496L (sv) | 1976-07-01 | 1976-07-01 | Sett for bekempning av virusinfektioner |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1585615A true GB1585615A (en) | 1981-03-11 |
Family
ID=20328354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB27464/77A Expired GB1585615A (en) | 1976-07-01 | 1977-06-30 | Composition and method for combating virus infections |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US4215113A (enExample) |
| JP (1) | JPS536428A (enExample) |
| AT (1) | AT369014B (enExample) |
| AU (1) | AU510809B2 (enExample) |
| BE (1) | BE856355A (enExample) |
| BG (1) | BG60834B2 (enExample) |
| CA (1) | CA1077848A (enExample) |
| CH (1) | CH641471A5 (enExample) |
| DE (1) | DE2728685C2 (enExample) |
| DK (1) | DK288877A (enExample) |
| FI (1) | FI772030A7 (enExample) |
| FR (1) | FR2356424A1 (enExample) |
| GB (1) | GB1585615A (enExample) |
| HK (1) | HK28984A (enExample) |
| IE (1) | IE45753B1 (enExample) |
| LU (2) | LU77666A1 (enExample) |
| MX (1) | MX9203635A (enExample) |
| MY (1) | MY8500125A (enExample) |
| NL (2) | NL180068C (enExample) |
| NO (1) | NO772299L (enExample) |
| SE (1) | SE7607496L (enExample) |
| SG (1) | SG80383G (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1140049A (en) | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
| DK564378A (da) * | 1977-12-22 | 1979-06-23 | Astra Laekemedel Ab | Fremgangsmaade til fremstilling af amidderivater til bekaempelse af virusinfektioner |
| DE2926799A1 (de) * | 1979-07-03 | 1981-01-15 | Bayer Ag | Phosphonoameisensaeurehydrazide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| DE2941384A1 (de) * | 1979-10-12 | 1981-04-23 | Bayer Ag, 5090 Leverkusen | Phosphono-hydroxy-essigsaeure, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| DE3127237A1 (de) * | 1981-07-10 | 1983-01-20 | Hoechst Ag, 6000 Frankfurt | Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung |
| WO1983002723A1 (en) * | 1982-02-12 | 1983-08-18 | Smith, Kendall, O. | Anti-viral compositions |
| US4902678A (en) * | 1982-02-12 | 1990-02-20 | Syntex (U.S.A.) Inc. | Anti-viral compositions |
| JPH0761814B2 (ja) * | 1984-09-10 | 1995-07-05 | 三菱化学株式会社 | 搬送装置 |
| JPS6194925A (ja) * | 1984-10-12 | 1986-05-13 | Mitsubishi Chem Ind Ltd | 搬送用装置 |
| JPS61217434A (ja) * | 1985-03-20 | 1986-09-27 | Mitsubishi Chem Ind Ltd | 搬送用装置 |
| GB8501374D0 (en) * | 1985-01-18 | 1985-02-20 | Wellcome Found | Treatment of aids |
| US4590064A (en) * | 1985-03-11 | 1986-05-20 | Colgate-Palmolive Company | Anticalculus oral composition |
| US4880619A (en) * | 1985-03-11 | 1989-11-14 | Colgate-Palmolive Company | Anticalculus oral composition |
| GB8512330D0 (en) * | 1985-05-15 | 1985-06-19 | Wellcome Found | Antiviral compounds |
| US4806532A (en) * | 1985-10-08 | 1989-02-21 | Mayo Foundation For Medical Education And Research | Inhibition of epithelial phosphate transport |
| EP0243352A1 (en) * | 1985-10-21 | 1987-11-04 | SERGIO, William | Method for reducing the risk or probability of infection from the aids virus (htlv-iii/lav/arv) |
| US6492352B1 (en) * | 1985-10-31 | 2002-12-10 | Astra Lakemedel Aktiebolag | Method for the control and treatment of acquired immunodeficiency syndrome (AIDS) |
| US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US6110901A (en) * | 1990-07-03 | 2000-08-29 | American Cyanamid Company | Method for treating RNA viral infections by using RNA chain terminators |
| SE9403861D0 (sv) * | 1994-11-09 | 1994-11-09 | Astra Ab | Novel medicinal use |
| US5696277A (en) * | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| EP0831842A4 (en) * | 1995-06-06 | 1998-08-19 | Univ Southern California | METHOD AND MEANS FOR INHIBITING PROPAGATION OF THE CYTOMEGALOVIRUS |
| US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| RU2116790C1 (ru) * | 1997-07-02 | 1998-08-10 | Закрытое акционерное общество "Рефарм" | Наружное противоинфекционное средство "рефарм" |
| RU2124881C1 (ru) * | 1997-11-26 | 1999-01-20 | Матковская Татьяна Александровна | Наружное лечебно-косметическое средство |
| FI980216A0 (fi) * | 1998-01-30 | 1998-01-30 | Bene Pharma Oy | Medicin foer behandling av vaorfor |
| US20040002079A1 (en) * | 1998-02-11 | 2004-01-01 | Gunn Robert B. | Sodium-phosphate cotransporter in lithium therapy for the treatment of mental illness |
| DE19940748A1 (de) * | 1999-08-27 | 2001-03-01 | Hugo Seinfeld | Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7455833B2 (en) * | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US20040131622A1 (en) * | 2002-07-15 | 2004-07-08 | Board Of Regents | Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids |
| US7790159B2 (en) * | 2002-07-15 | 2010-09-07 | Board Of Regents, The University Of Texas System | Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids |
| US7611704B2 (en) * | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7132452B2 (en) * | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| EP1603542A1 (en) * | 2003-03-14 | 2005-12-14 | Epistem Limited | Treatment and/or prevention of non-viral epithelial damage |
| US7424812B2 (en) | 2003-05-16 | 2008-09-16 | Stanton Concepts Inc. | Multiple function lock |
| US20090214676A1 (en) | 2005-04-30 | 2009-08-27 | Tissuetech, Inc. | Method for treating ocular demodex |
| US20080045482A1 (en) * | 2006-01-27 | 2008-02-21 | Adventrx Pharmaceuticals, Inc. | Compositions and methods for the treatment of viral infections |
| US8128968B2 (en) * | 2007-08-29 | 2012-03-06 | Tissuetech, Inc. | Compositions and methods for treating Demodex infestations |
| US9006219B2 (en) | 2008-03-12 | 2015-04-14 | Nektar Therapeutics | Oligomer-foscarnet conjugates |
| ES2578902B1 (es) * | 2014-12-29 | 2017-07-07 | Agencia Pública Empresarial Sanitaria Costa Del Sol | Uso de análogos del ión pirofosfato para el tratamiento de la infección por VPH |
| WO2022153334A1 (en) * | 2021-01-15 | 2022-07-21 | Jubilant Generics Ltd | Transmucosal dosage forms of foscarnet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3767795A (en) * | 1971-02-25 | 1973-10-23 | Abbott Lab | Method for combating certain virus infection |
| US3836650A (en) * | 1971-02-25 | 1974-09-17 | Abbott Lab | Method for combating marek's disease in poultry |
| DE2360797C2 (de) * | 1973-12-06 | 1985-05-23 | Henkel KGaA, 4000 Düsseldorf | Pharmazeutische Präparate |
-
1976
- 1976-07-01 SE SE7607496A patent/SE7607496L/xx unknown
-
1977
- 1977-06-20 US US05/807,783 patent/US4215113A/en not_active Expired - Lifetime
- 1977-06-25 DE DE2728685A patent/DE2728685C2/de not_active Expired
- 1977-06-27 AU AU26505/77A patent/AU510809B2/en not_active Expired
- 1977-06-27 IE IE1311/77A patent/IE45753B1/en not_active IP Right Cessation
- 1977-06-29 FI FI772030A patent/FI772030A7/fi not_active Application Discontinuation
- 1977-06-29 NL NLAANVRAGE7707235,A patent/NL180068C/xx not_active IP Right Cessation
- 1977-06-29 DK DK288877A patent/DK288877A/da not_active Application Discontinuation
- 1977-06-29 NO NO772299A patent/NO772299L/no unknown
- 1977-06-30 GB GB27464/77A patent/GB1585615A/en not_active Expired
- 1977-06-30 CA CA281,863A patent/CA1077848A/en not_active Expired
- 1977-06-30 FR FR7720100A patent/FR2356424A1/fr active Granted
- 1977-06-30 AT AT0465477A patent/AT369014B/de active Protection Beyond IP Right Term
- 1977-06-30 CH CH808577A patent/CH641471A5/de not_active IP Right Cessation
- 1977-06-30 LU LU77666A patent/LU77666A1/xx unknown
- 1977-07-01 BE BE178982A patent/BE856355A/xx not_active IP Right Cessation
- 1977-07-01 JP JP7797777A patent/JPS536428A/ja active Granted
-
1978
- 1978-12-21 US US05/971,931 patent/US4339445A/en not_active Expired - Lifetime
-
1982
- 1982-08-02 US US06/404,295 patent/US4665062A/en not_active Expired - Lifetime
-
1983
- 1983-12-20 SG SG803/83A patent/SG80383G/en unknown
-
1984
- 1984-03-29 HK HK289/84A patent/HK28984A/xx unknown
-
1985
- 1985-10-31 US US06/793,575 patent/US4771041A/en not_active Expired - Fee Related
- 1985-12-30 MY MY125/85A patent/MY8500125A/xx unknown
-
1992
- 1992-06-26 MX MX9203635A patent/MX9203635A/es unknown
-
1993
- 1993-06-10 NL NL930053C patent/NL930053I2/nl unknown
- 1993-06-16 LU LU88310C patent/LU88310I2/fr unknown
-
1994
- 1994-02-18 BG BG098492A patent/BG60834B2/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA1077848A (en) | 1980-05-20 |
| US4665062A (en) | 1987-05-12 |
| LU77666A1 (enExample) | 1977-10-07 |
| JPS562046B2 (enExample) | 1981-01-17 |
| DK288877A (da) | 1978-01-02 |
| NO772299L (no) | 1978-04-25 |
| NL930053I2 (nl) | 1994-01-03 |
| NL180068B (nl) | 1986-08-01 |
| DE2728685C2 (de) | 1982-09-16 |
| MY8500125A (en) | 1985-12-31 |
| CH641471A5 (de) | 1984-02-29 |
| JPS536428A (en) | 1978-01-20 |
| AT369014B (de) | 1982-11-25 |
| US4771041A (en) | 1988-09-13 |
| NL930053I1 (nl) | 1993-09-01 |
| LU88310I2 (fr) | 1994-05-04 |
| NL7707235A (nl) | 1978-01-03 |
| SE7607496L (sv) | 1978-01-02 |
| FR2356424A1 (fr) | 1978-01-27 |
| SG80383G (en) | 1984-08-03 |
| AU510809B2 (en) | 1980-07-17 |
| FR2356424B1 (enExample) | 1980-04-18 |
| US4339445A (en) | 1982-07-13 |
| ATA465477A (de) | 1982-04-15 |
| NL180068C (nl) | 1987-01-02 |
| IE45753B1 (en) | 1982-11-17 |
| US4215113A (en) | 1980-07-29 |
| FI772030A7 (enExample) | 1978-01-02 |
| DE2728685A1 (de) | 1978-01-12 |
| BE856355A (fr) | 1978-01-02 |
| MX9203635A (es) | 1992-09-01 |
| HK28984A (en) | 1984-04-06 |
| IE45753L (en) | 1978-01-01 |
| BG60834B2 (bg) | 1996-04-30 |
| AU2650577A (en) | 1979-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4215113A (en) | Method for combating virus infections | |
| Witkowski et al. | Design, synthesis, and broad spectrum antiviral activity of 1-. beta.-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide and related nucleosides | |
| Bean | Antiviral therapy: current concepts and practices | |
| NO154751B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme hydroksykarbonylfosfonsyreestere. | |
| JPH01500193A (ja) | 抗レトロウイルスおよびｂ型肝炎剤 | |
| KR890000762B1 (ko) | 1-β-D-아라비노프라노실-(E)-5-(2-할로게노비닐)우라실-5'-인산의 제조방법 | |
| KEATING | Antiviral agents | |
| US5039667A (en) | Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides | |
| EP0302760B1 (en) | Antiviral therapy for hepatitis b using 2',3'-dideoxynucleosides | |
| Neyts et al. | The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1, 3-dihydroxy-2-propoxy) methyl] purine is a potent and selective inhibitor of herpesvirus replication | |
| KR100196339B1 (ko) | Hiv-1 감염의 치료를 위한 펜시클로버 및 팜시클로버 및 관련된 구아닌 유도체 | |
| CA1261265A (en) | METHOD OF MEDICAL TREATMENT OF HUMAN VIRAL DISEASES UTILIZING 1-.beta.-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3- CARBOXAMIDE | |
| Shannon et al. | Comparison of the efficacy of vidarabine, its carbocyclic analog (cyclaradine), and cyclaradine-5'-methoxyacetate in the treatment of herpes simplex virus type 1 encephalitis in mice | |
| JPS60202822A (ja) | 抗ウイルス薬 | |
| US6492352B1 (en) | Method for the control and treatment of acquired immunodeficiency syndrome (AIDS) | |
| Miyai et al. | Synthesis and anti-deoxyribonucleic acid virus activity of certain 9-. beta.-D-arabinofuranosyl-2-substituted adenine derivatives | |
| US5674869A (en) | Pharmaceutical treatment | |
| JPH02247191A (ja) | 抗レトロウイルス剤としてのプリンおよびピリミジン非環状ヌクレオシドの環状モノホスフエート類 | |
| Machida et al. | Comparison of the in vitro and in vivo anti-herpes activities of 1-β-d-arabinofuranosylthymine and its 5′-monophosphate | |
| JPH0459731A (ja) | 抗ウイルス剤 | |
| JPH0544925B2 (enExample) | ||
| JPH06227982A (ja) | 抗ウイルス剤 | |
| Sethi | Zidovudine | |
| HK1004527B (en) | Penciclovir and famciclovir and related guanine derivatives for the treatment of the hiv-1 infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 704A | Declaration that licence is not available as of right for an excepted use (par. 4a/1977) | ||
| CTFF | Supplementary protection certificate filed |
Free format text: SPC/GB93/112, 930629 |
|
| CTFG | Supplementary protection certificate granted |
Free format text: SPC/GB93/112, 940121, EXPIRES:20020629 |
|
| CTFE | Supplementary protection certificate entered into force |
Free format text: SPC/GB93/112, 970630, EXPIRES:20020629 |
|
| PE20 | Patent expired after termination of 20 years |
Effective date: 19970629 |
|
| SPCE | Supplementary protection certificate expired |
Free format text: SPC/GB93/112, 20020629 |
|
| SPCE | Supplementary protection certificate expired |
Free format text: SPC/GB93/112, 20020629 |